A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest

CRISPR Therapeutics (CRSP) is back in focus after first quarter 2026 results showed revenue of US$1.46 million and a net loss of US$122.93 million, along with ongoing commentary about CASGEVY commercialization.

See our latest analysis for CRISPR Therapeutics.

The latest earnings update, CASGEVY launch commentary and the US$600 million convertible notes issue come against a backdrop of a 12.29% 90 day share price return, a 45.86% one year total shareholder return and weaker three and five year total shareholder returns. This suggests short term momentum has picked up after a tougher multi year stretch.

If gene editing is on your radar, this could be a useful moment to widen your watchlist and check out 32 healthcare AI stocks

With CRISPR Therapeutics posting losses, a recent share price rebound and some investors arguing the stock is undervalued on cash flow and P/B metrics, you need to ask: is there still an opportunity here, or is potential future growth already reflected in the price?

DCF suggests a large valuation gap: is the market too cautious?

CRISPR Therapeutics is trading at $54.83, while the SWS DCF model estimates a future cash flow value of $190.29, implying a large discount at the current price.

The DCF framework works by forecasting the cash flows a business is expected to generate in the future and then discounting those cash flows back to today using a required rate of return. The result is an estimate of what those future dollars are worth in present terms, which can then be compared directly with the share price.

For a company like CRISPR Therapeutics, which is currently loss making and does not yet have meaningful revenue at scale, a cash flow based approach anchors the discussion on what the existing pipeline might produce over time. In early stage biotech, this type of model can highlight the gap between current financials and what the market might be pricing in for future commercial success.

Look into how the SWS DCF model arrives at its fair value.

Result: DCF fair value of $190.29 (UNDERVALUED)

However, you still need to weigh the risk that CASGEVY uptake or broader pipeline progress falls short, especially given current revenue of US$4.10 million and a loss of US$568.53 million.

Find out about the key risks to this CRISPR Therapeutics narrative.

Another angle from market pricing

While the SWS DCF model flags a large discount, the market is sending a different signal through the P/B ratio. CRISPR Therapeutics trades at 2.9x book value, which is higher than the US Biotechs industry average of 2.4x, yet far below a peer average of 22.3x.

That mix of being relatively expensive versus the industry, but far cheaper than peers, suggests investors are splitting the difference between caution and optimism. This raises a simple question for you: is the stock priced for enough execution risk, or too much?

See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation, recent returns and fundamentals, sentiment around the stock is clearly split. It therefore makes sense to review the underlying data, weigh both sides and form a view quickly using the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop here, you risk missing stocks that better fit your style. Take a few minutes to scan focused shortlists built from detailed fundamentals.

• Target dependable income by reviewing companies in the 12 dividend fortresses that may suit a portfolio built around regular cash returns.
• Zero in on value opportunities by checking the screener containing 21 high quality undiscovered gems before attention and capital potentially crowd into the same stocks.
• Prioritise resilience by focusing on companies in the 70 resilient stocks with low risk scores so you can weigh potential upside against a more controlled risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com